Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Featured Story
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. First Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Mark Your Calendar: April 20 A $7 trillion global race for a critical new resource is underway. Fox News calls it the "new arms race." And Nvidia's CEO says this vital new resource will create more millionaires in the next 5 years than the internet created in the last two decades. On April 20, a major event could ignite a handful of under-the-radar stocks. Click here now for all the details
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in late March. This sharp downturn has many asking whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market's pessimism is warranted or whether the pullback creates a meaningful value opportunity. Separating the Signal From the NoiseAbbott's recent decline reflects two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, driven mainly by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and laid out a turnaround plan. CEO Robert B. Ford outlined pricing and promotion initiatives and pointed to a pipeline of at least eight new product launches planned for 2026, forecasting a return to growth in the second half of the year. The second factor is broader and external: a rotation of capital across the market. In times of economic optimism, investors often shift funds away from defensive sectors like the healthcare sector into higher-beta areas such as AI and the energy sector. That broad trend has weighed on many fundamentally sound healthcare companies, including Abbott, regardless of their individual performance. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works toward a near-term recovery, Abbott’s core businesses remain robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter, and helps offset the isolated weakness in Nutrition.
Medical Devices: The Medical Devices division is firing on multiple cylinders, driven by innovation in critical-care areas and strong end-market demand. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth engine. The product line — which enables users to track glucose without routine fingersticks — generated over $7.5 billion in sales in 2025 and remains a primary driver of Abbott’s performance. Cardiovascular Leadership: Abbott is also a leading player in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, and its Structural Heart business posted solid organic growth of 8.7%. These results reflect a portfolio of best-in-class products, such as MitraClip and TriClip, and a pipeline that includes the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also pursuing growth through strategic M&A. The planned acquisition of Exact Sciences would position Abbott as a leader in the rapidly expanding market for cancer diagnostics, adding a high-growth vertical centered on non-invasive screening tools like Cologuard. That combination of organic growth, product leadership, and targeted acquisitions has earned Wall Street respect. Analysts maintain a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47 — implying meaningful upside from current levels. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is one of the company’s most compelling attributes. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record underscores a deep commitment to returning capital to shareholders through multiple market cycles. The recent share-price decline has a direct benefit for new investors: a higher entry yield. At current levels, Abbott yields about 2.5%, providing an attractive income stream from a historically reliable payer. The dividend appears well supported: the payout ratio is roughly 68% of earnings but represents only about 37% of operating cash flow, indicating ample cash generation to cover distributions and room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott seems out of step with its business fundamentals. A temporary setback in one division and a broader market rotation have depressed the stock, but Abbott’s core growth engines are accelerating, its dividend remains secure, and strategic moves such as the Exact Sciences deal could unlock new growth avenues. For investors with a long-term horizon, the gap between price and underlying value presents a potential opportunity. The company’s diversified portfolio, strong cash flow, and history of returning capital to shareholders make it worth considering for those seeking steady growth and reliable income. |
